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scores for application in OA. Researchers can estimate overall
utility scores, compute QALYs, and perform cost-utility analy-
ses within a deﬁned range of uncertainty.
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OBJECTIVES: To determine the extent to which health items
identiﬁed from the perspective of patients with knee osteoarthri-
tis can be linked with the ICF; and to critically evaluate the 
ICF Comprehensive and Brief Core Sets for osteoarthritis.
METHODS: Items identiﬁed from a focus group study were
linked independently by two researchers based on the 10 a priori
linking rules. Both percentage agreement and kappa statistics
were calculated to measure inter-observer agreement. Any dis-
agreements were resolved by reaching a consensus among the
researchers. The categories linked with all items were compared
with the Comprehensive Core Set for osteoarthritis, while the
categories linked with those items reported as important by over
30% of subjects within each of 3 local ethnic groups (i.e.
Chinese, Malay, and Indian) were compared with the Brief Core
Set. Both comparisons were made only at the second level of the
ICF. RESULTS: Totally 74 items were linked with 44 different
ICF categories through 105 linkages with generally very good
inter-observer agreement. The 69 items were linked with the ICF
at the third or fourth levels. Both commonalities and disparities
were found through comparison between the categories linked
with these items and both Core Sets for osteoarthritis. CON-
CLUSIONS: In this study, all items could be successfully linked
with the ICF. The ICF Comprehensive Core Set demonstrated
general conceptual validity, while the Brief Core Set needs to be
supported by more empirical evidence in various socio-cultural
contexts. This study speciﬁcally complemented the development
and reﬁnement of both Core Sets from the perspective of patients
with knee osteoarthritis.
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OBJECTIVE: The 18-item ARTS questionnaire measures 4
dimensions relative to satisfaction with osteoarthritis treatment:
Effectiveness, Convenience, Tolerability, and Medical Care.
Validity studies and discriminant properties are reported in order
to establish a clinical relevant difference in the overall score and
a satisfaction threshold. METHODS: Two samples are com-
pared: a normative group of 163 used for linguistic validation
and an unsatisﬁed group of 1750 patients derived to a more tol-
erated treatment with COX-2. Groups are compared using t-test,
ANOVA and Tukey’s HSD. Sensitivity and related ﬁgures are
estimated using the ROC curve using as criteria the patients’
need of change in treatment (judged by the clinician). RESULTS:
The normative group renders a normal distribution of scores
(65.4 + 13.4, mean + SD), slightly biased above the 0–100 scaled
mid-point. The total score mean value for the unsatisﬁed sample
(52.5 + 11.1) was signiﬁcantly lower (p < 0.001) than for the
normative group, and much lower than the satisﬁed subgroup
(76.5 + 13.9). By dimensions, the larger difference between the
satisﬁed subgroup and the rest of patients who needed change
was observed in the Effectiveness dimension (dif = 34.1, t =
11.3), followed by Convenience (dif = 27.3, t = 10.1), Tolera-
bility (dif = 26.5, t = 5.3), and Medical Care (dif = 14.0, t = 5.7).
No differences were found between genders, neither in the nor-
mative group nor in the unsatisﬁed group. Sensitivity = 72%,
speciﬁcity = 77%, positive predictive value = 89% and negative
predictive value = 53% are obtained using a cut-off point of
69.18 determined from the clinical judgment of a need of change
in treatment (threshold value). Signiﬁcance differences in mean
score are also found between groups differing in tolerance to
actual treatment. CONCLUSION: ARTS is a sensitive instru-
ment and can be used to detect differences in the patients’ satis-
faction with osteoarthritis treatment. Differences between
groups of known satisfaction level are signiﬁcant and meaning-
ful, although it should be noted that the normative mean score
is above the scale midpoint.
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OBJECTIVES: To estimate change in quality of life (QoL) in
patients with psoriatic arthritis (PsA) receiving adalimumab vs.
placebo, as measured by the health utility measurement Short
Form 6D (SF-6D). METHODS: In a placebo-controlled, Phase
III trial of adalimumab (ADEPT), patients with active PsA
received adalimumab 40mg every other week (eow) or placebo
for 24 weeks. The SF-6D was estimated at baseline, 12 weeks
and 24 weeks using responses to the Short Form 36 (SF-36)
patient questionnaire. Multiple linear regression models were
estimated to explore the effects of age, sex, disease duration, con-
comitant therapies, baseline Health Assessment Questionnaire
Disability Index (HAQ DI), and the Psoriasis Area and Severity
Index (PASI). Patients were further differentiated as responders
or non-responders using the Psoriatic Arthritis Response Crite-
ria (PsARC) and an improvement in the PASI by 75% (PASI 75).
RESULTS: Baseline SF-6D values were 0.66 and 0.65 for the
adalimumab and placebo arms respectively. Overall, adali-
mumab improved health utility by 10.6% (SD = 18.9) in com-
parison to 2.9% (SD = 16.2) for placebo. Adalimumab was
particularly efﬁcacious in patients with skin involvement (13.7%
(SD = 20.9) versus 0.5% (SD = 17.0)). PsARC response was a
signiﬁcant predictor of utility improvement, and, for patients
with skin involvement, PASI 75 was also important CONCLU-
SIONS: These ﬁndings demonstrate that adalimumab was efﬁ-
cacious in improving PsA patients’ quality of life; and this
efﬁcacy was observed to an even higher degree in patients with
more skin involvement. Health utilities, when modeled with
associated costs over a patients’ lifetime, will facilitate the eco-
nomic evaluations of adalimumab.
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